Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of galantamine nano-brain targeted drug for nasal administration and preparation method thereof

A galantamine and brain-targeting technology, which is applied in the field of medicine, can solve problems such as inaccessibility of drugs, achieve protection and promote regeneration, have good biosorption, and improve brain-targeting effects

Active Publication Date: 2020-01-17
深圳市锦泰医药科技合伙企业有限合伙 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention aims at the shortcomings of the blood-brain barrier in existing drugs for treating senile dementia, and aims to provide a nano-brain-targeted drug for galantamine administered through the nose, so as to eliminate the problem that the drug cannot enter the brain tissue due to the existence of the blood-brain barrier. shortcoming

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of galantamine nano-brain targeted drug for nasal administration and preparation method thereof
  • A kind of galantamine nano-brain targeted drug for nasal administration and preparation method thereof
  • A kind of galantamine nano-brain targeted drug for nasal administration and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Preparation of nano-brain-targeted drug for intranasal administration of galantamine

[0044]The present embodiment provides a preparation method for the nasal administration of the anti-senile dementia targeted drug of the present invention, which specifically includes the following steps:

[0045] 1) Under a nitrogen atmosphere, the acetic acid-sodium acetate buffer solution of 10 mol of chitosan and 1 mol of potassium periodate were stirred and reacted at 4 °C for 48 h, and then 1 mol of ethylene glycol solution was added to the solution to stop the reaction, and the product was concentrated by rotary evaporation. Dialyzed in 1mol / L NaCl aqueous solution and deionized water for 48h to remove impurities, and the final product was freeze-dried to obtain hydroformyl chitosan (CS-CHO);

[0046] 2) Dissolve 1 mol of hydroformyl chitosan (CS-CHO) in 3 mol of DMSO, then add 1 mol of sodium chlorite, stir and react for 24 h, the product is concentrated by rotary evaporation ...

Embodiment 2

[0049] In vitro drug release study of galantamine loaded with chitosan

[0050] The drug was placed in a dialysis bag, and samples were periodically taken from the release medium for analysis of drug content. The specific process is as follows: freeze-dry the obtained drug solution, accurately weigh a certain amount, and then disperse it in 10ml of artificial cerebrospinal fluid by ultrasonic, put it in a dialysis bag (MWCO=12,000), put it in a 100ml conical flask, and add 40ml of artificial cerebrospinal fluid at a constant temperature In the shaker (set temperature 37°C, rotating speed 60r / min), sample 2ml at intervals, and add the same amount of release medium. This method can ensure that the polymer micelles remain in the dialysis bag, making the determination of the drug content more accurate.

[0051] The result is as figure 1 As shown, the release rate of galantamine hydrobromide solution is relatively fast, and it is basically released within 12 hours, and the cumula...

Embodiment 3

[0052] Example 3 Brain targeting evaluation

[0053] Healthy rats were taken and randomly divided into 4 groups, namely galantamine original drug group (original drug group); nano drug-loaded micelle group (experimental group); blank carrier micelle (blank group); normal saline (negative group) control group). 24h before the experiment, fasting but not water.

[0054] The rats were anesthetized by intraperitoneal injection of 2% pentobarbital sodium solution (40m / kg), supine and fixed on the rat board, the neck skin and muscles were incised, the trachea, esophagus, esophagus and trachea were separated, and tracheal intubation was performed. The upper segment is ligated to avoid the loss of the drug solution to the gastrointestinal tract after nasal administration. During the whole experiment, the anesthesia was supplemented timely to ensure that the rats were always under anesthesia.

[0055] Thirty minutes after the operation, the rats in the nasal administration group wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a nasal administration type nano-sized brain-targeting drug for galanthamine and a preparation method of the nasal administration type nano-sized brain-targeting drug for the galanthamine. The preparation method includes subjecting chitosan to oxidation by periodate so as to obtain different molecular weights of CS-CHO with chitosan chains containing o-dialdehyde functional groups, further, taking a DMSO (dimethyl sulfoxide) as a solvent and chlorous acid as an oxidizing agent to oxidize the o-dialdehyde functional groups into CS-COOH, and subjecting the CS-COOH and the galanthamine to esterification reaction so as to obtain the nano-sized brain-targeting drug. The nasal administration type nano-sized brain-targeting drug for the galanthamine has the advantages that the drug can envelop connecting tissues surrounding olfactory tracts or axons of olfactory receptor neurons through olfactory region mucous membranes to reach cerebral spinal fluid or the brain and can bypass blood-brain barriers to enter a central nervous system to be absorbed into the brain directly, and accordingly the drug is quick in action, needs no parenteral administration, avoids hepatic first-pass effect and is convenient to use by applying a dosing device.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a nano-brain targeted drug for intranasal administration of galantamine and a preparation method thereof. Background technique [0002] Alzheimer's disease (AD) is the most common type of senile dementia, ranking first among degenerative diseases of the central nervous system. It is characterized by progressive cognitive impairment and memory loss, abnormal mental behavior and life. Decreased ability is the main manifestation. With the aging of the age structure of human society, the incidence of Alzheimer's disease is increasing day by day, and it has become the third largest health killer after cardiovascular and cerebrovascular diseases and tumors. According to the 2010 Dementia Report, there are about 35.6 million AD patients in the world, and it is increasing at a rate of doubling every 20 years. By 2030, it will reach 65 million people, and most of them are in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/61A61K31/55A61K9/51A61K47/36A61P25/28
CPCA61K9/0043A61K9/5161A61K31/55
Inventor 吴正治段丽红
Owner 深圳市锦泰医药科技合伙企业有限合伙